Celopram

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Celopram

Property Description
Active ingredient Escitalopram (typically as the oxalate salt)
Form Film-coated tablets, Oral solution
Pharmacological class Selective Serotonin Reuptake Inhibitor (SSRI)
Common use Mood stabilization and emotional balance
Origin Synthetic, single-isomer compound

What Type of Medicine is Celopram (Escitalopram)?

Celopram is the brand name for the pharmaceutical substance Escitalopram, which is classified as a Selective Serotonin Reuptake Inhibitor (SSRI). This synthetic, prescription-only compound is clinically recognized for its targeted action on the central nervous system. The drug is typically presented as the oxalate salt of escitalopram, a chemical format designed for optimal systemic delivery following oral administration.

Escitalopram is structurally unique as a single-isomer; it is the pure S-enantiomer of its predecessor, citalopram. This composition provides high selectivity for the serotonin transporter, focusing its biological action primarily on the serotonin pathway.

Celopram's Composition, Form, and General Purpose

Celopram is supplied as a single-ingredient product (monotherapy), formulated primarily into film-coated tablets or an oral solution. The drug functions by inhibiting the neuronal reuptake of serotonin (5-HT), effectively increasing the concentration of this neurotransmitter in the synaptic space. This action provides foundational support for improving emotional regulation.

The highly selective mechanism of Escitalopram results in the modulation of serotonergic activity in the central nervous system. The overall goal is to re-establish chemical stability, assisting individuals in managing severe shifts in mood and psychological distress.

What side effects are possible with Celopram?

Possible Side Effects and Safety Information

The official safety profile for Celopram (Escitalopram) classifies documented adverse reactions by frequency and the body system affected, consistent with regulatory standards.

Frequency-Classified Adverse Reactions

Adverse reactions listed in regulatory documents are grouped based on the likelihood of their occurrence:

  • Very Common (Affecting 1 in 10 or more): Headache and Nausea.
  • Common (Affecting 1 in 100 to 1 in 10): Reactions related to the Nervous System (e.g., Dizziness, Insomnia, Somnolence), the Gastrointestinal System (e.g., Diarrhea, Dry Mouth), and Sexual Function (e.g., Decreased Libido, Ejaculation Disorder, Anorgasmia).
  • Uncommon or Rare: Less frequent reactions include Tachycardia, Alopecia, Epistaxis, Serotonin Syndrome, Anaphylactic reaction, and Bradycardia.

Documented Serious Safety Concerns

Official labeling requires specific attention to certain serious adverse reactions. These include the risk of Serotonin Syndrome, which involves significant changes in mental status and neuromuscular activity. Other serious concerns documented are QT Prolongation and the potential for a related heart rhythm disorder (Torsade de pointes), which are restrictions on use for individuals with pre-existing heart conditions. There is also an increased risk of Suicidal Thoughts and Behavior, particularly in children, adolescents, and young adults during the initial treatment period or following dose changes, as stated in regulatory warnings. Low serum sodium (Hyponatremia) is another documented risk, noted particularly in older adults.

Population and Time-Related Safety

Regulatory documents highlight safety considerations for specific groups. Caution is advised for the Older Adult population due to increased risk of Hyponatremia. Individuals with Hepatic Impairment may require a lower maximum dose due to reduced drug clearance. Furthermore, close patient observation is required during treatment initiation and dose adjustments due to the heightened, officially documented risk of serious events during these phases. Abrupt cessation is formally associated with discontinuation symptoms.

Overdose and Emergency Response

Overdose and When to Seek Help

The information in this section strictly reflects descriptions of overdose and mandated emergency actions as documented in official government regulatory sources (e.g., FDA and EMA prescribing information).


Documented Manifestations and Severe Outcomes

Overdoses involving Celopram (Escitalopram) often result in mild or no symptoms, but rare severe or life-threatening events are officially documented, particularly following co-ingestion with other substances. Manifestations typically affect three main systems:

  • Central Nervous System (CNS): Reported symptoms include dizziness, tremor, somnolence, and more seriously, convulsions (seizures) and coma.
  • Cardiovascular System: Documented effects include sinus tachycardia, hypotension, and critical ECG changes such as QT prolongation, with very rare reports of Ventricular arrhythmia and Torsade de Pointes.
  • Serotonin Syndrome: This potentially severe reaction is officially documented, characterized by changes in mental status and neuromuscular and autonomic instability.

Required Emergency Actions

Immediate medical attention is required for any suspected overdose of Celopram. The official labeling confirms that no specific antidote is known for escitalopram. Therefore, management is symptomatic and supportive, and specific monitoring is mandated. Urgent medical evaluation must include establishing an airway, conducting cardiac and vital sign monitoring, and specifically performing ECG monitoring due to the risk of cardiac complications. Procedural steps to consider include gastric lavage and administering activated charcoal.

Therapeutic Uses of Celopram

What Celopram Treats: Main Uses and Benefits

Celopram (citalopram) is a prescription medication primarily considered for the management of Major Depressive Disorder (MDD) in adults. It may be prescribed to help support the mitigation of core emotional symptoms of depression, including persistently low mood, feelings of guilt or worthlessness, and loss of interest in daily activities (anhedonia).

This medication is also utilized to help support positive changes in physical manifestations of depression, which can involve addressing disturbances in sleep patterns and assisting with the normalization of changes in appetite. A primary benefit of treatment is the contribution to the stabilization of the patient's overall emotional balance and functional capacity.

Quick Fact: Relief for Persistently Low Mood and Sleep Disturbances

In clinical practice, Celopram may also be considered for managing aspects of other conditions, such as Panic Disorder and Obsessive-Compulsive Disorder (OCD). The selection of Celopram for these indications is based on a healthcare provider's professional assessment.

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Celopram?

Celopram (Citalopram) is subject to strict eligibility rules based on regulatory guidance, particularly concerning drug interactions and cardiac risk.

Classification Populations and Conditions
Contraindicated (Must NOT Use) Patients taking Monoamine Oxidase Inhibitors (MAOIs), including Linezolid or intravenous Methylene Blue, or within 14 days of discontinuing an MAOI.
Patients concurrently taking Pimozide (an antipsychotic).
Individuals with known hypersensitivity (allergy) to citalopram or any inactive ingredients.
Use Restricted (Requires Caution/Lower Dose) Individuals 60 years of age and older: The maximum recommended daily dose is restricted to 20 mg.
Patients with hepatic impairment (reduced liver function): The maximum recommended daily dose is restricted to 20 mg.
Patients with congenital Long QT syndrome, or other conditions predisposing to QTc prolongation (e.g., recent acute myocardial infarction, bradycardia, uncompensated heart failure, or those taking other QTc-prolonging drugs).
Use Not Established Pediatric patients (under 18 years of age); safety and efficacy have not been established by the FDA for this population.

For pregnant or breastfeeding individuals, use is generally advised only when the potential benefit is deemed to outweigh the potential risk, as Citalopram is present in breast milk and may carry risks to the fetus/neonate.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Celopram (Escitalopram) has documented interactions based on both pharmacodynamic effects, such as increased serotonin activity, and pharmacokinetic effects, specifically enzyme metabolism via the Cytochrome P450 (CYP) system.

Contraindicated Combinations

Certain combinations are formally prohibited by regulatory documents due to serious risk, including Serotonin Syndrome or QTc interval prolongation.

Classification Interacting Agents
Serotonin Syndrome Risk Monoamine Oxidase Inhibitors (MAOIs), Linezolid, Intravenous Methylene Blue
Cardiac Risk Pimozide, other medicinal products known to prolong the QT interval

Interacting Product Categories

  • Serotonergic Drugs: Co-administration with other agents that increase serotonin levels, such as Triptans and Tramadol, requires caution due to the risk of Serotonin Syndrome.
  • Bleeding Risk Agents: Concomitant use with oral anticoagulants (e.g., Warfarin) and drugs that interfere with hemostasis, such as NSAIDs and Aspirin, may increase the official risk of bleeding/haemorrhage.
  • CYP Inhibitors: Inhibitors of CYP2C19 (e.g., Omeprazole) and CYP3A4 can lead to a documented increase in escitalopram plasma concentration.
  • CYP2D6 Substrates: Escitalopram is a weak CYP2D6 inhibitor; co-administration with drugs metabolized by this enzyme (e.g., Metoprolol) may increase the plasma concentration of the co-administered drug.

Other Regulatory Constraints

  • Timing Separation: A mandatory 14-day washout period must elapse when switching treatment between Celopram and an MAOI.
  • Supplements/Products: Alcohol and the herbal product St. John's Wort are advised to be avoided due to the potential for potentiated CNS effects or increased serotonergic risk.
  • Population Notes: Patients identified as CYP2C19 poor metabolizers are documented to have significantly higher systemic exposure.

Mechanism of Action

Selective Action on the Serotonin Transporter (SERT)

This mechanism focuses on the immediate molecular interaction: Celopram acts as a high-affinity inhibitor of the Serotonin Transporter (SERT), the protein responsible for clearing serotonin (5-HT) from the communication space between neurons. This targeted blockade prevents the active reuptake of 5-HT, increasing its availability and leading to elevated and prolonged serotonergic signaling throughout the Central Nervous System.

Time-Dependent Neural Circuit Rebalancing

This domain covers the subsequent adaptive processes required for the mechanism to reach its maximal alteration of signaling. The immediate rise in 5-HT triggers a negative feedback loop via presynaptic autoreceptors, which must desensitize and downregulate over time. This chronic physiological adaptation is required to fully modulate the functional activity of limbic circuits (e.g., the amygdala and hippocampus) which participate in affective and regulatory responses, and is linked to the long-term modulation of affective pathways and neural plasticity.

Mechanism Limitations: Specificity vs. Breadth

The high selectivity of the mechanism is a defining characteristic, as it exhibits minimal interaction with other major systems like norepinephrine or dopamine transporters. While this specificity focuses the action, the absence of effect on these alternate pathways is a mechanistic constraint.

Dosage and Administration Information

How to Use Celopram (Citalopram) — Administration Guidelines

This section describes the usage instructions for citalopram (Celopram). These instructions detail the procedure for administration and dosing.

Administration and Dosage

Feature Instruction
Route Oral administration only.
Frequency Taken once daily, either in the morning or evening.
With Meals May be taken with or without food.
Starting Dose The typical initial dose for most adults is 20 mg once daily.
Adult Maximum Dose The dose may be increased after a minimum of one week to a maximum of 40 mg once daily.

Population and Procedural Constraints

Specific guidelines apply to dosing to manage interactions and individual patient needs:

  • Geriatric Patients (Age 60 and older) and Specific Conditions: The maximum recommended daily dose is 20 mg. This lower maximum also applies to patients with reduced liver function or those taking certain concurrent medicines, such as CYP2C19 inhibitors.
  • Preparation: Oral tablets should be swallowed whole with water. Liquid oral solution must be shaken well and measured precisely using a calibrated device.
  • Discontinuation: Treatment should not be stopped abruptly. The dose must be gradually reduced over a period (e.g., one to two weeks) as guided by a healthcare professional.
  • Missed Dose: If a dose is missed, take it as soon as possible, unless it is nearly time for the next scheduled dose, in which case the missed dose should be skipped; do not double the dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Celopram

Evidence Base for Major Depressive Disorder (MDD)

The research for Celopram's evaluation in MDD primarily consists of numerous large-scale Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time, often comparing Celopram against a placebo or against other antidepressant medications. Studies monitored outcomes related to systemic or functional imbalance, such as the proportion of participants meeting predefined criteria for a reduction in measured symptom scores. Research was evaluated in populations that included Adults, Adolescents (ages 12-17), and Older Adults.

Findings describe patterns observed in the studies, which were relevant in trials assessing short-term or episodic symptom patterns, typically lasting 6 to 8 weeks. Maintenance studies extended the observation to six months or longer. Research highlights changes measured during the study period related to sustained measurement status following initial observation. Comparative evidence is limited in some head-to-head scenarios, and results apply only to the specific populations studied.

Evidence Base for Generalized Anxiety Disorder (GAD)

Research explored short-term symptom changes in studies where Celopram was evaluated for GAD, a condition marked by functional limitations. The core evidence comes from Randomized, Placebo-Controlled Trials. These trials focused on outcomes reflecting daily functioning or activity level, and outcomes related to physical discomfort. Studies monitored outcomes in both Adults and younger subjects, encompassing Children and Adolescents (ages 7 and older) with GAD.

Findings describe patterns observed in the studies related to subjects meeting predefined criteria for measured change in anxiety symptoms. A primary research limitation is that follow-up durations were limited for many large-scale trials, focusing predominantly on the acute, 8-week phase. As a result, long-term effects are not fully established when considering use well beyond this initial period.

What Research Gaps and Uncertainties Remain

The research provides context but not individual predictions, and evidence highlights what is known—and what is still uncertain. One key area of uncertainty is the general lack of systematic evaluation of efficacy beyond the initial acute treatment period for some conditions. Evidence quality varies across studies, and comparative evidence is limited or inconclusive in terms of long-term differences against certain treatments. Long-term effects are not fully established across all specific populations, and certainty remains low in these areas.

Frequently Asked Questions (FAQ)

Common questions about Celopram (FAQ)

Q: How long does it typically take for Celopram to start working for mood symptoms?

Official information indicates that initial improvement may not be noticeable during the first few weeks of treatment. For full benefits to be felt, it typically takes several weeks. Consistent use, as instructed by a healthcare provider, is generally recommended during this initial period.

Q: Is it normal to feel worse during the first few weeks of taking Celopram?

The official product information notes that for certain conditions, such as panic disorder, anxiety symptoms may briefly increase at the start of treatment, generally subsiding within two weeks. Worsening of depression or new suicidal thoughts can also occur during this initial phase, for which ongoing monitoring by a healthcare professional is important.

Q: Does Celopram have a risk of causing a change in body weight?

Regulatory-backed patient information indicates that changes in body weight may occur. Some users may experience weight loss initially, while others may gain weight over the long term, which can sometimes be due to a return of appetite.

Q: Do initial side effects from Celopram usually go away over time?

Studies and official information indicate that common initial side effects often improve as the body adjusts to the medicine. For example, headaches, tiredness, or drowsiness may improve or subside, often within the first one to two weeks of treatment.

Q: Is there a risk of long-term side effects associated with Celopram use?

Official safety data points to a lack of long-term safety information regarding growth and development in the pediatric patient population. Additionally, some side effects, such as those related to sexual function, have the potential to persist during long-term use.

Q: What is Serotonin Syndrome and what common drug interactions can lead to it?

Serotonin Syndrome is a serious condition caused by an excessive level of serotonin activity in the nervous system. Official warnings list symptoms including agitation, confusion, tremor, excessive sweating, and a rapid heartbeat. This risk is primarily associated with combining Celopram with other medicines that increase serotonin, such as MAOIs, Tramadol, and certain migraine treatments (Triptans).

Q: Does taking Celopram affect the effectiveness of birth control or contraceptives?

Regulatory-backed pharmacokinetic data suggests that no direct drug interaction is typically observed that would alter the concentrations of hormonal birth control, meaning the effectiveness of contraceptives is usually not affected.

Q: What is the guidance regarding Celopram use during pregnancy?

Regulatory guidance notes that the use of this medicine during pregnancy involves weighing the potential benefit against the potential risk to the fetus. Neonates exposed during the third trimester must be monitored for symptoms of poor adaptation, including respiratory distress and unstable body temperature.

Q: Why is close monitoring needed for young adults (under 25) when starting Celopram?

Close monitoring is required due to the official Boxed Warning issued by the FDA. This warning highlights an increased risk of suicidal thoughts and behaviors in young adults (up to age 25), adolescents, and children during the initial phase of treatment or following dose changes.

Q: What is the risk of having a manic episode if Celopram is taken by someone with undiagnosed bipolar disorder?

Official product information emphasizes caution when the drug is considered for individuals with a history of mania or hypomania. Regulatory documents specify that the drug is typically discontinued if a patient develops a manic phase.

Q: Is Celopram known to affect one's ability to drive or operate machinery?

Official regulatory warnings state that the drug may cause side effects such as dizziness, visual disturbance, or drowsiness. Because of these potential effects, it is generally recommended to use caution and avoid driving or operating complex machinery until a patient knows how the medication affects them.

Q: Is it possible to become dependent on Celopram?

Official patient care information clarifies that the drug is not considered habit-forming or addictive. However, abruptly stopping the medication can cause a physiological reaction known as discontinuation syndrome.

Q: What are 'antidepressant discontinuation symptoms' and what do they feel like?

Discontinuation symptoms are a collection of physiological effects that may occur when the drug is stopped. Symptoms may include dizziness, nausea, flu-like feelings, agitation, anxiety, and sensory disturbances (sometimes described as 'brain zaps').

Q: How long does it typically take for discontinuation symptoms to resolve after stopping Celopram?

Official patient information states that for many people, the symptoms may begin to taper off and resolve within four to six weeks. However, in some individuals, the symptoms can potentially last for several months or, rarely, longer.

Q: Is Celopram generally safe for long-term use?

Based on patient care information from authoritative sources, the drug is generally considered safe to be taken for a long period, even spanning several years, when used as prescribed.

Q: What is the significance of the FDA's 'Boxed Warning' on drugs like Celopram?

The Boxed Warning is the Food and Drug Administration's (FDA) most stringent safety warning. Its significance is to highlight a potential for serious safety concerns, in this case, the increased risk of suicidal thoughts and behaviors in young patients.

Q: Does Celopram cause night sweats or increased sweating?

Increased sweating is a documented adverse reaction. Official regulatory documents list increased sweating as one of the most commonly observed reactions associated with the use of the drug.

Q: Can Celopram be taken if a person has glaucoma?

Official product information indicates that the medication may cause angle-closure glaucoma. Caution is advised for patients, particularly those with untreated anatomically narrow angles in their eyes.

How should Celopram be stored and disposed of?

Celopram (Citalopram) should be stored securely to maintain its effectiveness and prevent accidental ingestion.

Storage Guidelines

Condition Recommendation
Temperature Store at room temperature, typically between 68 F and 77 F (20 C and 25 C).
Environment Keep the medication in its original, tightly closed container. Protect it from excessive heat and moisture; do not store it in a bathroom.
Safety Keep Celopram out of the reach and sight of children and pets at all times.

Disposal Guidelines

The most recommended method for disposing of unused or expired Celopram is through a local drug take-back program or a pharmacy-based mail-back service. If these options are not available, most non-controlled medicines, including Citalopram, can be disposed of in the household trash. To do this, mix the tablets with an undesirable substance, such as used coffee grounds or cat litter, place the mixture in a sealed plastic bag or container, and discard it in the trash. Do not flush this medication down the toilet unless specifically instructed by a professional.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Celopram found in:

A-Z Index: